In Australia, China, Europe, South Korea and USA
Suven Life Sciences announced that the Company secured patents in Australia (201136550), China (CN103079566), Europe (2694492), South Korea (10-1538239) and USA (9079894) to their New Chemical Entities (NCE's) for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2031, 2030, 2031, 2030 and 2031 respectively. The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.With these new patents, Suven has a total of twenty two (22) granted product patents in Australia, nineteen (19) granted patents from China, seventeen (17) granted patents from Europe, seventeen (17) granted patents from South Korea and twenty three (23) granted patents from USA.
Powered by Capital Market - Live News
